Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
Strategies and innovations related to how clinical professionals are utilizing technology internal and external to their organizations to advance clinical trials. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
With mounting evidence that cancer research and biomedical discovery are slowing even as a 45 percent increase in cancer cases is projected by 2030, the National Patient Advocate Foundation (NPAF) – a national non-profit organization providing the patient's voice in improving access to quality cancer care – today released a blueprint to accelerate the delivery of promising new treatments to patients and launched a new grassroots movement called Project Innovation to drive action.
Issued as a call to action, the new white paper – Securing the Future of Innovation in Cancer Treatment – is the result of consultation with biomedical researchers, medical innovators, patient advocates, clinicians and policymakers and offers a roadmap for addressing the pervasive obstacles slowing the pace of cancer discovery. Among the barriers cited are a nearly 20 percent drop in government-funded basic research since 2010 and a steady decline in venture capital investment in biotechnology since 2007.
Also impeding progress are logistical, bureaucratic, institutional and regulatory obstacles that add years to scientific discovery and drug development, such as added steps and inefficiencies in the clinical trials process, duplicative and conflicting standards, auditing mandates, increasing regulatory requirements and delays in review decisions. As a result, it takes nine or more years from discovery to approval for a new cancer therapy compared to an average time of two years for HIV drugs. Further, because drug development is an uncertain process, a 2010 Tufts University study puts the cost of developing one innovative cancer drug at upwards of $1 billion.
"This report represents a wakeup call for all Americans and is intended to spark a national movement to make cancer innovation a national priority," said Nancy Davenport-Ennis, NPAF's founder and chairman. "Cancer kills 1,600 Americans every day and this number will only increase in the years ahead unless we commit as a nation to hasten the pace of medical discovery. It is time to put cancer innovation on the national agenda and press for solutions that will save lives instead of continuing a one-sided conversation on the cost of treatment."
Project Innovation to Spearhead a National Dialogue on Cancer Innovation
Project Innovation is a collaboration of leaders from national cancer advocacy organizations, providers, biomedical research institutions, the business community and industry to put cancer innovation on the policy agenda.
Three Pillars of Innovation